C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. (Q40684870)

22 September 2017

1 reference

title

C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. (English)

1 reference

22 September 2017

vascular leak syndrome

1 reference

1 reference

C E Hack

1

1 reference

22 September 2017

A C Ogilvie

2

1 reference

22 September 2017

B Eisele

3

1 reference

22 September 2017

A J Eerenberg

4

1 reference

22 September 2017

J Wagstaff

5

1 reference

22 September 2017

L G Thijs

6

1 reference

22 September 2017

1 January 1993

1 reference

22 September 2017

Intensive Care Medicine

1 reference

22 September 2017

19 Suppl 1

1 reference

22 September 2017

S19-28

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01738946

22 September 2017

0 references

cites work

The pathogenesis of sepsis

1 reference

https://api.crossref.org/works/10.1007%2FBF01738946

Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01738946

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01738946

Formation of prostanoids during intravascular complement activation in the rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01738946

Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01738946

NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01738946

The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01738946

The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01738946

Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins).

21 January 2018

1 reference

12 December 2020

Serum Complement Levels in Bacteremia Due to Gram-Negative Organisms

1 reference

12 December 2020

Septic shock. Hemodynamics and pathogenesis

1 reference

12 December 2020

C5a-mediated release of interleukin 6 by human monocytes

1 reference

12 December 2020

Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate

1 reference

12 December 2020

Cachectin: more than a tumor necrosis factor

1 reference

12 December 2020

Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa

1 reference

12 December 2020

Proteolytic inactivation of plasma C1- inhibitor in sepsis

1 reference

12 December 2020

C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes.

1 reference

12 December 2020

Interactions of leukocyte integrins with intercellular adhesion molecule 1 in the production of inflammatory vascular injury in vivo. The Shwartzman reaction revisited

1 reference

12 December 2020

The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments

1 reference

12 December 2020

Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis

1 reference

12 December 2020

Anaphylatoxins: possible roles in disease

1 reference

12 December 2020

Contact factors in health and disease

1 reference

12 December 2020

Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis

1 reference

12 December 2020

Studies on the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock

1 reference

12 December 2020

Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors

1 reference

12 December 2020

Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself

1 reference

12 December 2020

The systemic complement activation caused by interleukin-2/lymphokine-activated killer-cell therapy of cancer causes minimal systemic neutrophil activation

1 reference

12 December 2020

Complement activation via the alternative pathway by purified Salmonella lipopolysaccharide is affected by its structure but not its O-antigen length

1 reference

12 December 2020

Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase

1 reference

12 December 2020

Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages

1 reference

12 December 2020

Biochemistry and pathophysiology of human C1 inhibitor: current issues.

1 reference

12 December 2020

Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma

1 reference

12 December 2020

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

1 reference

12 December 2020

Manifestations of sepsis

1 reference

12 December 2020

Anaphylatoxin formation in sepsis

1 reference

12 December 2020

Management of septic shock: present and future

1 reference

12 December 2020

Activation of the properdin pathway of complement in patients with gram-negative of bacteremia

1 reference

12 December 2020

The regulation of human factor XIIa by plasma proteinase inhibitors

1 reference

12 December 2020

Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects

1 reference

12 December 2020

Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties.

1 reference

12 December 2020

Anaphylatoxin Generation in Multisystem Organ Failure

1 reference

12 December 2020

Microvascular effects of anaphylatoxins C3a and C5a

1 reference

12 December 2020

Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase.

1 reference

12 December 2020

The coagulation-kinin pathway of human plasma

1 reference

12 December 2020

Septic shock: treatment

1 reference

12 December 2020

The Biochemistry and Pathophysiology of the Contact System of Plasma

1 reference

12 December 2020

Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency

1 reference

12 December 2020

Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes

1 reference

12 December 2020

Human plasma proteinase inhibitors

1 reference

12 December 2020

Role of the contact system in fibrinolysis

1 reference

12 December 2020

The inhibition of activated factor XII (hageman factor) by antithrombin III: The effect of other plasma proteinase inhibitors

1 reference

12 December 2020

Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex

1 reference

12 December 2020

IL-2 induction of IL-1 beta mRNA expression in monocytes. Regulation by agents that block second messenger pathways

1 reference

12 December 2020

Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.

1 reference

12 December 2020

Pathophysiology of bacteremia

1 reference

12 December 2020

On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity

1 reference

12 December 2020

Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS)

1 reference

12 December 2020

Plasma kallikrein activation and inhibition during typhoid fever

1 reference

12 December 2020

The contact activation system: biochemistry and interactions of these surface-mediated defense reactions

1 reference

12 December 2020

A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein

1 reference

12 December 2020

IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans

1 reference

12 December 2020

The role of complement in the induction of thromboplastin synthesis

1 reference

12 December 2020

Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity

1 reference

12 December 2020

Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients

1 reference

12 December 2020

Regulation of the pathophysiology of tumor necrosis factor

1 reference

12 December 2020

A model for the interplay of inflammatory mediators in sepsis--a study in 48 patients

1 reference

12 December 2020

EFFECTS OF BRADYKININ ON FOREARM VENOUS TONE AND VASCULAR RESISTANCE IN MAN

1 reference

12 December 2020

Terminal complement complexes and anaphylatoxins in septic and ischemic patients

1 reference

12 December 2020

Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates

1 reference

12 December 2020

Endotoxin-induced shock in the rat. A role for C5a

1 reference

12 December 2020

Mechanisms of activation of the classical pathway of complement by Hageman factor fragment

1 reference

12 December 2020

Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value

1 reference

12 December 2020

Tissue plasminogen activator release in vivo in response to vasoactive agents

1 reference

12 December 2020

The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1

1 reference

12 December 2020

Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases

1 reference

12 December 2020

Structure and function of the anaphylatoxins

1 reference

12 December 2020

Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers.

1 reference

12 December 2020

Guinea pig Hageman factor as a vascular permeability enhancement factor.

1 reference

12 December 2020

Thromboembolism and bleeding tendency in congenital factor XII deficiency--a study on 74 subjects from 14 Swiss families

1 reference

12 December 2020

Plasma Kallikrein and Hageman Factor in Gram-Negative Bacteremia

1 reference

12 December 2020

Kinetic analysis of plasminogen activation by purified plasma kallikrein

1 reference

12 December 2020

Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases.

1 reference

12 December 2020

In vivo catabolism of α1-antichymotrypsin is mediated by the Serpin receptor which binds α1-proteinase inhibitor, antithrombin III and heparin cofactor II

1 reference

12 December 2020

Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia

1 reference

12 December 2020

An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein

1 reference

12 December 2020

Human plasma kallikrein releases neutrophil elastase during blood coagulation

1 reference

12 December 2020

Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema.

1 reference

12 December 2020

Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment

1 reference

12 December 2020

Quantification of functional and inactivated alpha 2-macroglobulin in sepsis

1 reference

12 December 2020

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

1 reference

12 December 2020

The classical complement pathway: activation and regulation of the first complement component.

1 reference

12 December 2020

Activation of the classical pathway of complement by Hageman factor fragment

1 reference

12 December 2020

Inactivation of kallikrein in human plasma

1 reference

12 December 2020

Complement activation and high-dose of interleukin-2

1 reference

12 December 2020

Activation of plasminogen by human plasma kallikrein

1 reference

12 December 2020

C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha

1 reference

12 December 2020

Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways.

1 reference

12 December 2020

Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

1 reference

12 December 2020

Tumor necrosis factor in the pathophysiology of infection and sepsis

1 reference

12 December 2020

The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons

1 reference

12 December 2020

Purified human plasma kallikrein aggregates human blood neutrophils

1 reference

12 December 2020

C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes

1 reference

12 December 2020

Activation of Purified Human Plasma Prekallikrein Triggered by Cell Wall Fractions of Escherichia coli and Staphylococcus aureus

1 reference

12 December 2020

Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

12 December 2020

Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes

1 reference

12 December 2020

Contribution of Plasma Protease Inhibitors to the Inactivation of Kallikrein in Plasma

1 reference

12 December 2020

Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis

1 reference

12 December 2020

Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay

1 reference

12 December 2020

Human leukocyte IgG Fc receptors

1 reference

12 December 2020

Accentuated formation of the terminal C5b-9 complement complex in patient plasma precedes development of the adult respiratory distress syndrome

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity

1 reference

12 December 2020

Molecular Biology and Chemistry of the Alternative Pathway of Complement

1 reference

12 December 2020

Regulatory functions of the vascular endothelium

1 reference

12 December 2020

Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface

1 reference

12 December 2020

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

1 reference

12 December 2020

C1-esterase inhibitor substitution in sepsis

1 reference

12 December 2020

Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor

1 reference

12 December 2020

Increased plasma levels of interleukin-6 in sepsis

1 reference

12 December 2020

Granulocyte aggregation as a manifestation of membrane interactions with complement: possible role in leukocyte margination, microvascular occlusion, and endothelial damage

1 reference

12 December 2020

Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor)

1 reference

12 December 2020

Tissue destruction by neutrophils

1 reference

12 December 2020

C5a induction of human interleukin 1. Synergistic effect with endotoxin or interferon-gamma

1 reference

12 December 2020

Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta

1 reference

12 December 2020

Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo

1 reference

12 December 2020

Surface-mediated defense reactions. The plasma contact activation system

1 reference

12 December 2020

Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects.

1 reference

12 December 2020

Endotoxin, prekallikrein, complement and systemic vascular resistance. Sequential measurements in man.

1 reference

12 December 2020

Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis

1 reference

12 December 2020

Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats

1 reference

12 December 2020

Activation of the contact system in lethal hypotensive bacteremia in a baboon model

1 reference

12 December 2020

Interleukin-2 therapy enhances salicylate oxidation by blood granulocytes

1 reference

12 December 2020

The effects of bacterial endotoxins on host mediation systems. A review

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01738946

1 reference

22 September 2017

1 reference